Oconee Memorial Hospital
- Type
- Teaching hospital
- Where
- Seneca, SC
- Medicare CCN
- 420009
- Received
- $998,765 in 160 records, 2024 ($119,959 general, $878,805 research)
- Source
- CMS Open Payments search ↗
On this site
- Federal award recipient: OCONEE MEMORIAL HOSPITAL INC Fuzzy (name and state)
- Lobbying client: OCONEE MEMORIAL HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 29 | $119,959 |
| 2024 | Research payment | 131 | $878,805 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 2 | $568,904 | 2024 |
| QOL Medical, LLC | 5 | $84,620 | 2024 |
| Impulse Dynamics (USA) Inc. | 15 | $62,354 | 2024 |
| Arthrex, Inc. | 2 | $48,261 | 2024 |
| Smith+Nephew, Inc. | 2 | $45,000 | 2024 |
| Surmodics, Inc. | 6 | $29,195 | 2024 |
| Analog Devices Inc. | 1 | $26,945 | 2024 |
| ABBVIE INC. | 4 | $24,383 | 2024 |
| Eli Lilly and Company | 2 | $21,139 | 2024 |
| National Marrow Donor Program | 4 | $17,885 | 2024 |
| Applied Medical Resources Corporation | 1 | $15,197 | 2024 |
| Cook Incorporated | 4 | $10,874 | 2024 |
| Abbott Laboratories | 7 | $10,104 | 2024 |
| AngioDynamics, Inc. | 1 | $7,000 | 2024 |
| Stryker Corporation | 4 | $6,552 | 2024 |
| ZOLL Circulation Inc | 1 | $4,251 | 2024 |
| Neurocrine BioSciences, Inc. | 32 | $3,198 | 2024 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $3,000 | 2024 |
| Novo Nordisk AS | 58 | $2,373 | 2024 |
| MicroVention, Inc. | 1 | $2,024 | 2024 |
| ZOLL Medical Corporation | 1 | $2,000 | 2024 |
| Boston Scientific Corporation | 3 | $1,500 | 2024 |
| INSTYLLA, INC. | 1 | $1,000 | 2024 |
| Novo Nordisk Inc | 1 | $1,000 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 131 | $878,805 |
| Grant | 8 | $47,374 |
| Space rental or facility fees (teaching hospital only) | 10 | $26,298 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 4 | $17,885 |
| Education | 3 | $16,622 |
| Long term medical supply or device loan | 4 | $11,779 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Stryker Corporation | $264 | Long term medical supply or device loan | In-kind items and services | ISOFLEX LAL Device, PATIENT HANDLING - PH | 2024 | |
| 2024-12-31 | Stryker Corporation | $264 | Long term medical supply or device loan | In-kind items and services | ISOFLEX LAL Device, PATIENT HANDLING - PH | 2024 | |
| 2024-12-30 | Surmodics, Inc. | $600 | Research payment | Cash or cash equivalent | Pounce Device, Pounce Thrombectomy System | Pounce Thrombectomy System Retrospective Registry (PROWL) | 2024 |
| 2024-12-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-12-12 | Impulse Dynamics (USA) Inc. | $2,326 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-12-10 | Abbott Laboratories | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Structural Heart | 2024 | |
| 2024-11-21 | Arthrex, Inc. | $7,020 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-11-20 | Novo Nordisk AS | $607 | Research payment | Cash or cash equivalent | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-11-15 | Novo Nordisk AS | $63 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-11-15 | Novo Nordisk AS | $63 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-11-15 | Novo Nordisk AS | $63 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-11-15 | Novo Nordisk AS | $63 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-11-15 | Novo Nordisk AS | $63 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-11-15 | Novo Nordisk AS | $63 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-11-15 | Novo Nordisk AS | $63 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-11-15 | Novo Nordisk AS | $63 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-11-15 | Novo Nordisk AS | $63 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-11-15 | Novo Nordisk AS | $63 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-11-15 | Novo Nordisk AS | $63 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-11-08 | Eli Lilly and Company | $9 | Research payment | In-kind items and services | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC | 2024 | |
| 2024-11-06 | Impulse Dynamics (USA) Inc. | $1,535 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-10-31 | Stryker Corporation | $3,024 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TARGET Device, DETACHABLE COIL | 2024 | |
| 2024-10-25 | Arthrex, Inc. | $41,241 | Research payment | In-kind items and services | 2024 | ||
| 2024-10-25 | National Marrow Donor Program | $3,710 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-10-23 | Impulse Dynamics (USA) Inc. | $2,230 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-10-10 | Impulse Dynamics (USA) Inc. | $4,157 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-10-04 | QOL Medical, LLC | $25,590 | Research payment | Cash or cash equivalent | SUCRAID Drug, THERAPY FOR CSID | QOL Pediatric Sucraid | 2024 |
| 2024-09-23 | Cook Incorporated | $416 | Grant | In-kind items and services | AMPLATZ Device, Peripheral Intervention | 2024 | |
| 2024-09-23 | Cook Incorporated | $405 | Grant | In-kind items and services | CXI Device, Peripheral Intervention | 2024 | |
| 2024-09-23 | Cook Incorporated | $53 | Grant | In-kind items and services | AMPLATZ Device, Peripheral Intervention | 2024 | |
| 2024-09-20 | Ipsen Biopharmaceuticals, Inc | $3,404 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | 2024 |
| 2024-09-18 | Surmodics, Inc. | $12,542 | Research payment | Cash or cash equivalent | Pounce Device, Pounce Thrombectomy System | Pounce Thrombectomy System Retrospective Registry (PROWL) | 2024 |
| 2024-09-11 | Impulse Dynamics (USA) Inc. | $12,306 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-09-06 | Cook Incorporated | $10,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-08-30 | Applied Medical Resources Corporation | $15,197 | Education | In-kind items and services | GelPOINT Mini Advanced Access Platform Device, SPECIALTY ACCESS | 2024 | |
| 2024-08-30 | Abbott Laboratories | $712 | Education | In-kind items and services | 2024 | ||
| 2024-08-21 | Novo Nordisk AS | $607 | Research payment | Cash or cash equivalent | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-08-15 | Novo Nordisk Inc | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Ozempic Drug, Diabetes | 2024 | |
| 2024-08-15 | Novo Nordisk AS | $30 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-08-15 | Novo Nordisk AS | $30 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-08-15 | Novo Nordisk AS | $30 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-08-15 | Novo Nordisk AS | $30 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-08-15 | Novo Nordisk AS | $30 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-08-15 | Novo Nordisk AS | $30 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-08-15 | Novo Nordisk AS | $30 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-08-15 | Novo Nordisk AS | $30 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-08-15 | Novo Nordisk AS | $30 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-08-14 | MicroVention, Inc. | $2,024 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-08-08 | Surmodics, Inc. | $600 | Research payment | Cash or cash equivalent | Pounce Device, Pounce Thrombectomy System | Pounce Thrombectomy System Retrospective Registry (PROWL) | 2024 |
| 2024-08-07 | Impulse Dynamics (USA) Inc. | $3,849 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-08-06 | ABBVIE INC. | $8,625 | Research payment | Cash or cash equivalent | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse | 2024 | |
| 2024-07-31 | Abbott Laboratories | $455 | Research payment | Cash or cash equivalent | Xience Skypoint Device, VASCULAR | XIENCE Skypoint Large Vessel Post Approval Study | 2024 |
| 2024-07-26 | National Marrow Donor Program | $3,835 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-07-15 | Impulse Dynamics (USA) Inc. | $1,128 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $473 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $473 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $473 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $473 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $45 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $45 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $45 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $14 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $13 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-06-13 | QOL Medical, LLC | $15,551 | Research payment | Cash or cash equivalent | SUCRAID Drug, THERAPY FOR CSID | QOL Pediatric Sucraid | 2024 |
| 2024-06-12 | Impulse Dynamics (USA) Inc. | $5,099 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-06-06 | Surmodics, Inc. | $13,004 | Research payment | Cash or cash equivalent | Pounce Device, Pounce Thrombectomy System | Pounce Thrombectomy System Retrospective Registry (PROWL) | 2024 |
| 2024-06-06 | Stryker Corporation | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | POWER-PRO Device, EMS | 2024 | |
| 2024-06-05 | Analog Devices Inc. | $26,945 | Research payment | Cash or cash equivalent | Sensinel CPM Wearable Device, CARDIOLOGY | Feasibility and Efficacy Study of the CardioPulmonary Monitoring (CPM) System in Patients with Chronic Heart Failure | 2024 |
| 2024-05-31 | Boston Scientific Corporation | $500 | Grant | In-kind items and services | Device, General - Structural Heart_IC | 2024 | |
| 2024-05-31 | Boston Scientific Corporation | $500 | Grant | In-kind items and services | Device, General - Structural Heart_IC | 2024 | |
| 2024-05-31 | Boston Scientific Corporation | $500 | Grant | In-kind items and services | Device, General - Structural Heart_IC | 2024 | |
| 2024-05-20 | Neurocrine BioSciences, Inc. | $44 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-05-16 | Impulse Dynamics (USA) Inc. | $1,001 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-05-08 | QOL Medical, LLC | $22,141 | Research payment | Cash or cash equivalent | SUCRAID Drug, THERAPY FOR CSID | QOL Pediatric Sucraid | 2024 |
| 2024-05-06 | ZOLL Medical Corporation | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Defibrillator Device, Resuscitation | 2024 | |
| 2024-04-26 | National Marrow Donor Program | $4,140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-04-17 | Impulse Dynamics (USA) Inc. | $915 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-04-13 | Smith+Nephew, Inc. | $33,750 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-04-13 | Smith+Nephew, Inc. | $11,250 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-04-04 | ABBVIE INC. | $8,458 | Research payment | Cash or cash equivalent | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse | 2024 | |
| 2024-04-01 | Ipsen Biopharmaceuticals, Inc | $565,500 | Research payment | In-kind items and services | Tazverik Drug, Oncology | A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | 2024 |
| 2024-03-31 | Impulse Dynamics (USA) Inc. | $5,230 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-03-25 | AngioDynamics, Inc. | $7,000 | Long term medical supply or device loan | In-kind items and services | Auryon Laser System 100-120 Vac Device, ET | 2024 | |
| 2024-03-19 | QOL Medical, LLC | $7,930 | Research payment | Cash or cash equivalent | SUCRAID Drug, THERAPY FOR CSID | QOL Pediatric Sucraid | 2024 |
| 2024-03-19 | ZOLL Circulation Inc | $4,251 | Long term medical supply or device loan | Cash or cash equivalent | Temperature Management System Device, Temperature Management | 2024 | |
| 2024-03-15 | ABBVIE INC. | $2,250 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ven | 2024 |
| 2024-03-12 | Impulse Dynamics (USA) Inc. | $5,763 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-03-11 | ABBVIE INC. | $5,050 | Research payment | Cash or cash equivalent | A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936 (Anti-ADAM9 Antibody Drug Conjug | 2024 | |
| 2024-03-07 | Surmodics, Inc. | $2,250 | Research payment | Cash or cash equivalent | Pounce Device, Pounce Thrombectomy System | Pounce Thrombectomy System Retrospective Registry (PROWL) | 2024 |
| 2024-03-07 | Surmodics, Inc. | $198 | Research payment | Cash or cash equivalent | Pounce Device, Pounce Thrombectomy System | Pounce Thrombectomy System Retrospective Registry (PROWL) | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-04 | Novo Nordisk AS | $4 | Research payment | In-kind items and services | Alhemo Drug, Hemophilia | NN7415-4807 | 2024 |
| 2024-03-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-02-21 | Impulse Dynamics (USA) Inc. | $3,979 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-02-15 | Impulse Dynamics (USA) Inc. | $6,500 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-02-07 | INSTYLLA, INC. | $1,000 | Research payment | Cash or cash equivalent | VERGE MICROCATHETER Device, Liquid Embolics for Interventional Radiology | A PROSPECTIVE, NON-RANDOMIZED SINGLE-ARM PILOT STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF INSTYLLA HES FOR TRANSCAT | 2024 |
| 2024-01-30 | Abbott Laboratories | $712 | Education | In-kind items and services | 2024 | ||
| 2024-01-26 | Abbott Laboratories | $3,155 | Research payment | Cash or cash equivalent | XIENCE SKYPOINT Device, VASCULAR | A Clinical Investigation to Assess the Abbott Next Generation Drug Eluting Stent 48mm Everolimus Eluting Coronary Stent | 2024 |
| 2024-01-26 | Neurocrine BioSciences, Inc. | $761 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-01-19 | Impulse Dynamics (USA) Inc. | $6,330 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) | 2024 |
| 2024-01-17 | Abbott Laboratories | $2,818 | Research payment | Cash or cash equivalent | Xience Skypoint Device, VASCULAR | XIENCE Skypoint Large Vessel Post Approval Study | 2024 |
| 2024-01-12 | Eli Lilly and Company | $21,129 | Research payment | Cash or cash equivalent | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC | 2024 | |
| 2024-01-12 | National Marrow Donor Program | $6,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-01-11 | Abbott Laboratories | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XIENCE SKYPOINT Device, Vascular | 2024 | |
| 2024-01-11 | Neurocrine BioSciences, Inc. | $44 | Research payment | Cash or cash equivalent | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntingt | 2024 | |
| 2024-01-03 | QOL Medical, LLC | $13,406 | Research payment | Cash or cash equivalent | SUCRAID Drug, THERAPY FOR CSID | QOL Pediatric Sucraid | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Seneca, SC, county Oconee County, SC, state South Carolina; placed by its city name.
| Measure | Place (city or town) Seneca, SC | County Oconee County, SC | State South Carolina |
|---|---|---|---|
| Population B01003 | 8,993 | 80,469 | 5,296,225 |
| Population, 2020 census P1 | 8,850 | 78,607 | 5,118,425 |
| Median age B01002 | 39.6 | 47.3 | 40.2 |
| Under 18 B01001 | 18.5% | 19.1% | 21.4% |
| 65 and over B01001 | 20.4% | 24.9% | 18.9% |
| Households B11001 | 4,082 | 34,515 | 2,117,989 |
| Foreign born B05002 | 2.6% | 4.2% | 5.8% |
| Median household income B19013 | $52,022 | $62,388 | $69,324 |
| Median family income B19113 | $74,864 | $80,443 | $86,707 |
| Per capita income B19301 | $34,204 | $39,360 | $39,236 |
| Poverty rate B17001 | 22.1% | 17.6% | 14.1% |
| Unemployment rate B23025 | 8.9% | 5.9% | 4.9% |
| Civilian labor force B23025 | 4,606 | 35,647 | 2,560,429 |
| Mean commute (minutes) B08013 | 16.0 | 23.9 | 25.6 |
| Bachelor's degree or higher B15003 | 29.1% | 28.7% | 32.1% |
| Housing units B25001 | 4,648 | 42,100 | 2,443,039 |
| Owner-occupied B25003 | 51.4% | 76.2% | 71.9% |
| Renters B25003 | 48.6% | 23.8% | 28.1% |
| Median home value B25077 | $240,000 | $237,100 | $259,000 |
| Median gross rent B25064 | $807 | $881 | $1,180 |
| White, not Hispanic B03002 | 72.8% | 83.1% | 61.9% |
| Black B03002 | 17.4% | 5.2% | 24.6% |
| Hispanic or Latino B03002 | 6.4% | 6.2% | 7.4% |
| Asian B03002 | 0.8% | 0.7% | 1.7% |
| American Indian and Alaska Native B03002 | 0.8% | 0.4% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Seneca, SC.
Comments